relatlimab,nivolumab
bms
['neopredict', 'lcsm,(-blcsm)', 'nivo']
proud to see our neopredict trial presented at #esmo2022 . primary endpoint reached: 100% of patients safely underwent surgery. promise in nivo + rela combo with 30% mpr rate. great collab . #lcsm 
MD MSc, Thoracic Oncology & Respiratory Medicine, master in hospital and health care management Hasselt - Belgium - PhD candidate Amsterdam/Leiden - he/him